🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareCan someone explain this to me like I am five? Page 2

Can someone explain this to me like I am five?

nick_newbie Fri, Feb 13, 2026 at 1:50 AM 7 replies 898 viewsPage 2 of 2
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Feb 13, 2026 at 3:38 AM#6
HPLC_Greg said:
Read four things before the headline number.

This is where I part company with the consensus forming above. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

28 23CarlaRPh_TPA, steph_laguna, fiona_glasgow and 25 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Feb 13, 2026 at 4:20 AM#7
nick_newbie said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…
nick_newbie said:
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].

The NNT was 8, which is comparable to metformin for T2DM prevention. That's a strong clinical argument for this approach.

27 22Admin, Dr.Martinez, mike_mod and 24 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Feb 13, 2026 at 5:02 AM#8
Dr.BariatricHTX said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

26 21maya_sedona, stefan_berlin, Dr.EM_Chicago and 23 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
Feb 13, 2026 at 5:44 AM#9

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Feb 13, 2026 at 11:44 AM
25 20Dr.PulmRoch, maya_sedona, stefan_berlin and 22 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Feb 13, 2026 at 9:07 AM#10

Closing the loop on my own question.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

45 20wanda_boise, NurseAsh_DET, BenResearch_OR and 42 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register